S&P 500   5,083.62 (+0.27%)
DOW   38,917.49 (-0.08%)
QQQ   438.49 (+0.74%)
AAPL   180.26 (-0.64%)
MSFT   409.27 (+0.38%)
META   487.98 (+0.82%)
GOOGL   137.32 (+0.69%)
AMZN   175.05 (+1.09%)
TSLA   200.19 (-0.92%)
NVDA   792.94 (+2.10%)
NIO   5.70 (+4.97%)
AMD   189.66 (+7.43%)
BABA   74.22 (-0.50%)
T   17.03 (+0.41%)
F   12.40 (+0.81%)
MU   90.32 (+0.68%)
CGC   3.29 (-2.08%)
GE   155.80 (+0.12%)
DIS   111.22 (+0.38%)
AMC   4.30 (-13.83%)
PFE   26.81 (-0.85%)
PYPL   60.33 (+0.13%)
XOM   104.53 (+0.20%)
S&P 500   5,083.62 (+0.27%)
DOW   38,917.49 (-0.08%)
QQQ   438.49 (+0.74%)
AAPL   180.26 (-0.64%)
MSFT   409.27 (+0.38%)
META   487.98 (+0.82%)
GOOGL   137.32 (+0.69%)
AMZN   175.05 (+1.09%)
TSLA   200.19 (-0.92%)
NVDA   792.94 (+2.10%)
NIO   5.70 (+4.97%)
AMD   189.66 (+7.43%)
BABA   74.22 (-0.50%)
T   17.03 (+0.41%)
F   12.40 (+0.81%)
MU   90.32 (+0.68%)
CGC   3.29 (-2.08%)
GE   155.80 (+0.12%)
DIS   111.22 (+0.38%)
AMC   4.30 (-13.83%)
PFE   26.81 (-0.85%)
PYPL   60.33 (+0.13%)
XOM   104.53 (+0.20%)
S&P 500   5,083.62 (+0.27%)
DOW   38,917.49 (-0.08%)
QQQ   438.49 (+0.74%)
AAPL   180.26 (-0.64%)
MSFT   409.27 (+0.38%)
META   487.98 (+0.82%)
GOOGL   137.32 (+0.69%)
AMZN   175.05 (+1.09%)
TSLA   200.19 (-0.92%)
NVDA   792.94 (+2.10%)
NIO   5.70 (+4.97%)
AMD   189.66 (+7.43%)
BABA   74.22 (-0.50%)
T   17.03 (+0.41%)
F   12.40 (+0.81%)
MU   90.32 (+0.68%)
CGC   3.29 (-2.08%)
GE   155.80 (+0.12%)
DIS   111.22 (+0.38%)
AMC   4.30 (-13.83%)
PFE   26.81 (-0.85%)
PYPL   60.33 (+0.13%)
XOM   104.53 (+0.20%)
S&P 500   5,083.62 (+0.27%)
DOW   38,917.49 (-0.08%)
QQQ   438.49 (+0.74%)
AAPL   180.26 (-0.64%)
MSFT   409.27 (+0.38%)
META   487.98 (+0.82%)
GOOGL   137.32 (+0.69%)
AMZN   175.05 (+1.09%)
TSLA   200.19 (-0.92%)
NVDA   792.94 (+2.10%)
NIO   5.70 (+4.97%)
AMD   189.66 (+7.43%)
BABA   74.22 (-0.50%)
T   17.03 (+0.41%)
F   12.40 (+0.81%)
MU   90.32 (+0.68%)
CGC   3.29 (-2.08%)
GE   155.80 (+0.12%)
DIS   111.22 (+0.38%)
AMC   4.30 (-13.83%)
PFE   26.81 (-0.85%)
PYPL   60.33 (+0.13%)
XOM   104.53 (+0.20%)
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.49
$0.86
52-Week Range
N/A
Volume
243,500 shs
Average Volume
137,683 shs
Market Capitalization
$14.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.63

AcelRx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$4.63 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.00mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$7,300 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.40) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.44 out of 5 stars

Medical Sector

674th out of 958 stocks

Pharmaceutical Preparations Industry

323rd out of 450 stocks


ACRX stock logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.


ACRX Stock News Headlines

AcelRx Pharmaceuticals (NASDAQ:ACRX) Now Covered by StockNews.com
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
AcelRx CEO buys 10,000 shares
Positive Report for Acelrx (ACRX) from H.C. Wainwright
Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/29/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRX
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.63
High Stock Price Target
$5.00
Low Stock Price Target
$4.25
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$47.76 million
Pretax Margin
-3,711.25%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$2.65 per share

Miscellaneous

Free Float
16,443,000
Market Cap
$14.58 million
Optionable
Optionable
Beta
0.52
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














ACRX Stock Analysis - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings
or view top-rated stocks.

What is AcelRx Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1 year target prices for AcelRx Pharmaceuticals' stock. Their ACRX share price targets range from $4.25 to $5.00. On average, they predict the company's stock price to reach $4.63 in the next twelve months.
View analysts price targets for ACRX
or view top-rated stocks among Wall Street analysts.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to analysts' expectations of $1.20 million. During the same quarter in the previous year, the firm earned ($2.00) earnings per share.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals shares reverse split before market open on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.39%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRX) was last updated on 2/29/2024 by MarketBeat.com Staff